ADMA BIOLOGICS, INC. (36)

Browse by Contract Category

Contracts

Underwriting Agreement, by and between the Company and Raymond James & Associates, Inc., as representative of the several underwriters named therein, dated as of October 21, 2021 (Filed With SEC on October 21, 2021)
Amendment to Employment Agreement, dated as of September 29, 2021, by and between the Company and Brian Lenz (Filed With SEC on October 1, 2021)
Distribution Agreement, dated September 3, 2021, by and between ADMA Biologics, Inc. and Raymond James & Associates, Inc (Filed With SEC on September 3, 2021)
Open Market Sale AgreementSM, dated May 28, 2021, by and between ADMA Biologics, Inc. and Jefferies LLC (Filed With SEC on May 28, 2021)
Amendment to Employment Agreement, dated as of September 29, 2021, by and between the Company and Adam Grossman (Filed With SEC on October 1, 2021)
Form of Retention Bonus Agreement (Filed With SEC on October 1, 2021)
Separation Agreement and Release, dated August 6, 2021, by and between ADMA Biologics, Inc. and James Mond (Filed With SEC on August 11, 2021)
Second Amendment to Plasma Purchase Agreement, effective as of May 12, 2021, by and between ADMA BioManufacturing, LLC and Grifols Worldwide Operations LTD (Filed With SEC on May 12, 2021)
Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2021)
Warrant to Purchase Stock, dated December 8, 2020, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on March 25, 2021)
Amendment No. 2 to Sale Agreement, dated as of February 3, 2021 (Filed With SEC on February 3, 2021)
Rights Agreement, dated as of December 16, 2020, by and between ADMA Biologics, Inc. and Continental Stock Transfer and Trust Company, as rights agent (Filed With SEC on December 16, 2020)
Amendment No. 2 to Credit Agreement and Guaranty, dated December 8, 2020 (Filed With SEC on December 9, 2020)
Note, dated December 8, 2020, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on December 9, 2020)
Amendment to Open Market Sale AgreementSM, dated November 5, 2020, by and between ADMA Biologics, Inc. and Jefferies LLC (Filed With SEC on November 5, 2020)
Open Market Sale AgreementSM, dated August 5, 2020, by and between ADMA Biologics, Inc. and Jefferies LLC (Filed With SEC on August 5, 2020)
Note, dated March 20, 2020, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on March 20, 2020)
Amendment 3 to the Amended and Restated Agreement for Services, effective as of November 7, 2019, by and between ADMA Biologics, LLC and Areth LLC (Filed With SEC on March 13, 2020)
Amendment 2 to the Amended and Restated Agreement for Services, effective as of September 27, 2018, by and between ADMA Biologics, LLC and Areth LLC (Filed With SEC on March 13, 2020)
Amendment 1 to the Amended and Restated Agreement for Services, effective as of September 25, 2017, by and between ADMA Biologics, LLC and Areth LLC (Filed With SEC on March 13, 2020)
Description of Capital Stock of ADMA Biologics, Inc (Filed With SEC on March 13, 2020)
Underwriting Agreement by and among the Company and the Underwriters dated as of February 6, 2020 (Filed With SEC on February 7, 2020)
Amendment #1 to Transition Services Agreement, dated as of August 29, 2019, by and between ADMA Biomanufacturing, LLC and Biotest Pharmaceuticals Corporation (Filed With SEC on September 5, 2019)
Underwriting Agreement by and among the Company and the Underwriters dated as of May 16, 2019 (Filed With SEC on May 17, 2019)
Warrant to Purchase Stock, dated May 3, 2019, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on May 3, 2019)
Note, dated May 3, 2019, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on May 3, 2019)
Amendment No. 1 to Credit Agreement and Guaranty, dated as of May 3, 2019, by and among the Company, ADMA Plasma Biologics, Inc., ADMA Bio Centers Georgia Inc., ADMA... (Filed With SEC on May 3, 2019)
Transition Services Agreement, dated as of January 1, 2019, by and between the Company and Biotest Pharmaceuticals Corporation (Filed With SEC on March 13, 2019)
Credit Agreement and Guaranty, dated as of February 11, 2019, by and among the Company, ADMA Plasma Biologics, Inc., ADMA Bio Centers Georgia Inc., ADMA BioManufacturing, LLC, and... (Filed With SEC on February 12, 2019)
Security Agreement, dated as of February 11, 2019, by and among the Company, ADMA Plasma Biologics, Inc., ADMA Bio Centers Georgia Inc., ADMA BioManufacturing, LLC, and Perceptive... (Filed With SEC on February 12, 2019)
Warrant to Purchase Stock, dated February 11, 2019, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on February 12, 2019)
Note, dated February 11, 2019, issued by the Company to Perceptive Credit Holdings II, LP (Filed With SEC on February 12, 2019)
Amended and Restated Employment Agreement, dated as of January 29, 2019, by and between ADMA Biologics, Inc. and Brian Lenz (Filed With SEC on January 29, 2019)
Amended and Restated Employment Agreement, dated as of January 29, 2019, by and between ADMA Biologics, Inc. and Dr. James Mond (Filed With SEC on January 29, 2019)
Amended and Restated Employment Agreement, dated as of January 29, 2019, by and between ADMA Biologics, Inc. and Adam Grossman (Filed With SEC on January 29, 2019)
Fifth Amendment to Plasma Purchase Agreement, effective as of January 1, 2019, by and between ADMA Biologics, Inc. and Grifols Worldwide Operations Limited (Filed With SEC on January 2, 2019)